Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer

J Chemother. 1991 Jun;3(3):194-7. doi: 10.1080/1120009x.1991.11739092.

Abstract

Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks. Five patients (41%) achieved an objective response with one complete regression. The median duration of response was 4.5 months and the median duration of survival was 8 months. Drug related toxicity consisted mainly of leukopenia (8 pts), nausea and vomiting (6 pts), anemia (7 pts) and thrombocytopenia (4 pts).

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Carcinoma / drug therapy*
  • Cisplatin / administration & dosage
  • Female
  • Humans
  • Methotrexate / administration & dosage
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Neoplasm Metastasis
  • Remission Induction
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Mitoxantrone
  • Cisplatin
  • Methotrexate